Skip to main content
. 2019 May 31;9(13):3966–3979. doi: 10.7150/thno.32172

Figure 4.

Figure 4

(A) IC50 values of DTSPs-3 and DTSLs against HeLa cells. (B) Schematic illustration of the design and apparatus for evaluation of the therapeutic potential of drug-loaded vesicles in combination with HIFU hyperthermia and ablation. (C) Fluorescence signals of DOX in HeLa cells incubated with drug-loaded vesicles before and after HIFU hyperthermia. The scale bar represents 20 μm. (D) IC50 values of HeLa cells after treatment with DTSPs-3 and DTSLs in combination with HIFU hyperthermia. (E) Viability of HeLa cells after different treatments.